Table 1.
Patient characteristics prior matching
| Parameter | CyberKnife (n = 104) | VMAT (n = 38) | p Value |
|---|---|---|---|
| Age (years) | 68.9 ± 7.3 | 72.5 ± 6.1 | 0.0069 |
| Risk group | 0.72 | ||
| Low | 10 (10%) | 4 (11%) | |
| Intermediate | 60 (57%) | 19 (50%) | |
| High | 34 (33%) | 15 (40%) | |
| Neoadjuvant ADT | 95 (91%) | 34 (90%) | 0.75 |
| Duration of neoadjuvant ADT (months) | 8.3 ± 11.1 | 6.3 ± 0.9 | 0.29 |
| Comorbidity | |||
| Antithrombotic therapy | 13 (13%) | 6 (16%) | 0.59 |
| Diabetes | 14 (14%) | 6 (16%) | 0.79 |
| Previous TURP | 2 (2%) | 1 (3%) | 0.99 |
| Medication to improve dysuria at baseline | 17 (16.3%) | 7 (18.4%) | 0.8 |
| Pre-treatment IPSS | 0.96 | ||
| Mild (0–7) | 33 (32%) | 13 (34%) | |
| Moderate (8–19) | 59 (57%) | 21 (55%) | |
| Severe (20–35) | 11 (11%) | 4 (11%) | |
| Prostate volume (cc) | 25.9 ± 9.6 | 26.0 ± 15.3 | 0.97 |
Data are presented as number (%) or mean ± SD
VMAT volumetric modulated arc therapy; ADT androgen deprivation therapy; TURP transurethral resection of the prostate; IPSS International Prostate Symptom Score